Skip to main content
SAWAI GROUP HOLDINGS Co., Ltd. logo

SAWAI GROUP HOLDINGS Co., Ltd. — Investor Relations & Filings

Ticker · 4887 ISIN · JP3323040000 T Manufacturing
Open in API
Filings indexed 70 across all filing types
Latest filing 2026-05-22 M&A Activity
Country JP Japan
Listing T 4887

About SAWAI GROUP HOLDINGS Co., Ltd.

https://www.sawaigroup.holdings/

SAWAI GROUP HOLDINGS Co., Ltd. is a holding company that operates through its subsidiaries in the pharmaceutical field. The group's core activities encompass the research, development, manufacture, and marketing of medical products. It is primarily known for its extensive portfolio of high-quality generic pharmaceuticals, which serve as bioequivalent alternatives to branded drugs across various therapeutic areas, including treatments for hypertension, dyslipidemia, and diabetes. In addition to prescription generics, the company also handles over-the-counter (OTC) and other ethical drugs. The group is committed to enhancing healthcare access and affordability by providing reliable and cost-effective medications to patients and medical professionals.

Recent filings

Filing Released Lang Actions
完全子会社間の吸収合併に関するお知らせ
M&A Activity Classification · 85% confidence The document is a corporate announcement titled “完全子会社間の吸収合併に関するお知らせ” (Notice of absorption‐type merger between wholly owned subsidiaries). It outlines the board resolution, merger schedule, merger method, and company details of the surviving and disappearing entities. This is clearly an M&A announcement. It is not a proxy statement or US SEC filing, but rather a standard merger notice, fitting the M&A Activity category (Code: TAR).
2026-05-22 Japanese
連結子会社からの配当金受領に関するお知らせ
Regulatory Filings Classification · 85% confidence The document is a brief corporate announcement (約381文字) informing stakeholders that the parent company will receive a dividend from its consolidated subsidiary, including the amount and accounting impact. It is not an announcement of dividends paid to the company’s external shareholders (DIV), nor is it a full financial report, management discussion, or other specialized filing. It is therefore best classified as a general regulatory announcement that does not fit any more specific category (RNS).
2026-05-22 Japanese
発行登録書（株券､社債券等）
Capital/Financing Update Classification · 95% confidence The document is a 'Shelf Registration Statement' (発行登録書) filed with the Kanto Local Finance Bureau by Sawai Group Holdings. This document is a regulatory filing used to register securities (in this case, corporate bonds) for future issuance. It does not fit into specific categories like 10-K, IR, or ER, and is not a mere announcement of a report (RPA). Therefore, it falls under the 'Regulatory Filings' category as a general regulatory document.
2026-01-29 Japanese
発行登録追補書類（株券､社債券等）
Capital/Financing Update Classification · 100% confidence The document is a 'Supplement to the Shelf Registration Statement' (発行登録追補書類) filed with the Kinki Local Finance Bureau by Sawai Group Holdings Co., Ltd. It details the issuance of unsecured corporate bonds (social bonds). This type of document is a formal regulatory filing related to capital raising and financing activities, which falls under the 'Capital/Financing Update' category.
2025-12-05 Japanese
確認書
Regulatory Filings Classification · 100% confidence The document is a 'Confirmation Letter' (確認書) filed under the Financial Instruments and Exchange Act, signed by the CEO and CFO, confirming the accuracy of the contents of a semi-annual report. According to the 'Certification Rule', documents that are primarily officer certifications or attestations, even if they reference a specific report type (like a semi-annual report), should be classified as Regulatory Filings (RNS) rather than the report itself. H1 2025
2025-11-14 Japanese
半期報告書－第5期(2025/04/01－2026/03/31)
Interim / Quarterly Report Classification · 100% confidence The document is a '半期報告書' (Semi-Annual Report) filed with the Kanto Local Finance Bureau in Japan. It contains detailed financial statements, management discussion and analysis (MDA), and business performance metrics for the interim period (April 1, 2025, to September 30, 2025). This fits the definition of an Interim/Quarterly Report (IR) as it provides comprehensive financial data and analysis for a period shorter than a full fiscal year. H1 2026
2025-11-14 Japanese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.